(Q36618959)

15 August 2017

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study (English)

1 reference

15 August 2017

1 reference

1 reference

H Ueoka

1

1 reference

15 August 2017

M Tabata

2

1 reference

15 August 2017

K Kiura

3

1 reference

15 August 2017

T Shibayama

4

1 reference

15 August 2017

K Gemba

5

1 reference

15 August 2017

Y Segawa

6

1 reference

15 August 2017

K Chikamori

7

1 reference

15 August 2017

T Yonei

8

1 reference

15 August 2017

S Hiraki

9

1 reference

15 August 2017

M Harada

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

5-6

1 reference

15 August 2017

984-990

1 reference

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Toxicity and response criteria of the Eastern Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362688

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

20 September 2018

1 reference

12 December 2020

Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer

1 reference

12 December 2020

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

12 December 2020

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

1 reference

12 December 2020

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690157

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

10070901

1 reference